The above-mentioned immunotherapy targeting tau does not eliminate the neurodegenerative changes already present in AD patients, but inhibits the spread of pathogenic tau to unaffected brain regions, thereby delaying or even stopping the pathological changes of tau (9). The gene discussed is MAPT; the disease is Alzheimer disease.